Eli Lilly’s Omvoh Shows Long-Term Efficacy in Crohn’s Disease

Eli Lilly and Company has announced new data from the VIVID-2 open-label extension study, showing that Omvoh provided long-term clinical and endoscopic benefits for patients with moderately to severely active Crohn's disease. The findings highlight the potential of Omvoh as a durable treatment option, even for patients who previously failed biologic therapies.

Omvoh works by targeting interleukin-23p19 (IL-23p19), a protein involved in intestinal inflammation, reports Eli Lilly. In the study, patients who had received one year of treatment in the Phase 3 VIVID-1 trial and continued in VIVID-2 demonstrated sustained response rates. Among those in clinical remission at the one-year mark, 92.9% remained in remission at two years, based on the Crohn's Disease Activity Index. Additionally, 87.6% maintained endoscopic response, defined as a significant reduction in disease severity observed through endoscopy. For patients in endoscopic remission after one year, 78.6% retained remission at the two-year point.

Of the patients who had not reached remission at the end of VIVID-1, 60.8% achieved remission in the second year. Additionally, 35.4% of those not in endoscopic remission after the first year reached that milestone in the second year. Eli Lilly argues that these findings suggest that extended treatment with Omvoh can provide additional benefits over time.

During the second year of treatment, 6.8% of patients with an endoscopic response at one year reported a serious adverse event, while 0.8% discontinued treatment due to adverse events. Eli Lilly highlights that these results reinforce Omvoh’s potential as a long-term treatment option for Crohn’s disease.

The US Food and Drug Administration approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults in January 2025. The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion in December 2024, and regulatory applications are underway in other countries, including Canada, Japan, and China. Omvoh is also approved in 44 countries for the treatment of ulcerative colitis.